Genetic/Familial High-Risk Assessment: Breast and Ovarian
Mary B. Daly(Fox Chase Cancer Center), Jeffrey N. Weitzel(Cancer Genetics (United States)), P. Kelly Marcom(Duke University), Gwen Reiser(University of California San Diego), Heather Hampel(City of Hope), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Tuya Pal(Vanderbilt University Medical Center), Boris Pasche(University of Michigan–Dearborn), Robert L. Nussbaum(National Institutes of Health), Virginia Kaklamani(Northwestern University), Kristen M. Shannon(Massachusetts General Hospital), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Wendy Kohlmann(University of Utah), Allison W. Kurian(Stanford University), Carolyn Farrell(Roswell Park Comprehensive Cancer Center), Saundra S. Buys(University of Utah), Jeffrey R. Smith(Orlando Health), Jennifer E. Axilbund(Johns Hopkins University), Elizabeth M. Swisher(University of Washington), Stephen B. Gruber(University of Michigan), Susan Friedman(Facing Our Risk of Cancer Empowered), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Salil Goorha(Roswell Park Comprehensive Cancer Center), Judy E. Garber(Dana-Farber Cancer Institute)
Cited by 650
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k